Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PROTIDE PHARMA (PPMD : OTC)
 
 • Company Description   
Protide Pharmaceuticals, Inc. is engaged in researching, developing, manufacturing, and marketing cell biology products that are used in the propagation of cells derived from mammals, including humans, and other species. These cell growth products are used primarily in academic, pharmaceutical and other commercial laboratories to improve the growth, productivity and quality of cell-derived medical and other biological products such as vaccines, monoclonal antibodies, interferons, and human growth factor.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.22 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 1.26
52 Week High: $0.22
52 Week Low: $0.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 12.64%
12 Week 0.00% 9.94%
Year To Date 0.00% 22.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1311 Helmo Avenue
-
Saint Paul,MN -
USA
ph: 651-730-1500
fax: 651-730-8900
None http://www.protidepharma.com
 
 • General Corporate Information   
Officers
- - -
- - -
- - -
- - -
- - -

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74371A103
SIC: 2836
Fiscal Year
Fiscal Year End: August
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 1.26
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
02/28/22 - -
11/30/21 - -
08/31/21 - -
ROA
02/28/22 - -
11/30/21 - -
08/31/21 - -
Current Ratio
02/28/22 - -
11/30/21 - -
08/31/21 - -
Quick Ratio
02/28/22 - -
11/30/21 - -
08/31/21 - -
Operating Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Net Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Pre-Tax Margin
02/28/22 - -
11/30/21 - -
08/31/21 - -
Book Value
02/28/22 - -
11/30/21 - -
08/31/21 - -
Inventory Turnover
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Equity
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Capital
02/28/22 - -
11/30/21 - -
08/31/21 - -
 

Powered by Zacks Investment Research ©